|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 48/00 | (2006.01) |
| A61P 37/00 | (2006.01) |
| (11) | Number of the document | 2782602 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12790904.2 |
| Date of filing the European patent application | 2012-11-23 | |
| (97) | Date of publication of the European application | 2014-10-01 |
| (45) | Date of publication and mention of the grant of the patent | 2019-06-26 |
| (46) | Date of publication of the claims translation | 2019-10-10 |
| (86) | Number | PCT/EP2012/073501 |
| Date | 2012-11-23 |
| (87) | Number | WO 2013/076262 |
| Date | 2013-05-30 |
| (30) | Number | Date | Country code |
| 11190826 | 2011-11-25 | EP | |
| 201261595230 P | 2012-02-06 | US |
| (72) |
ADMYRE, Charlotte, SE
ZARGARI, Arezou, SE
VON STEIN, Oliver, SE
VON STEIN, Petra, SE
|
| (73) |
Index Pharmaceuticals AB,
Tomtebodavägen 23a, 171 77 Stockholm,
SE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Nukleotidas DIMS0-150, skirtas lėtinio aktyvaus opinio kolito gydymui |
| Nucleotide DIMS0-150 for use in the treatment of chronic active ulcerative colitis |
| Payment date | Validity (years) | Amount | |
| 2023-10-16 | 12 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-11-23 |